Permanent hairloss from chemotherapy significantly impacts patients' mental health and social life, highlighting the need for better patient education and support.
A sugar gel was claimed to trigger hair regrowth, but users reported no results and potential cancer risks. The discussion included comparisons to minoxidil and skepticism about the effectiveness of the sugar treatment.
Amplifica's new injectable treatment for androgenetic alopecia shows a 15% increase in hair thickness and coarseness in 60 days. The treatment is in early human trials and offers a promising alternative to hormone-relatedhairloss treatments.
Creatine may increase DHT levels, but its impact on hairloss is unclear and not well-studied. Many users report no significant hairloss while using creatine alongside finasteride, though some experience increased shedding.
Federal funding cuts have delayed PP405 research, affecting hairloss treatment progress, though clinical trials will continue. The discussion highlights PP405's potential compared to minoxidil and finasteride and stresses the importance of government-funded research.
Androgenic alopecia (AGA) might have evolved to reduce prostate cancer risk by increasing UV exposure to the scalp, but this theory is debated. Treatments like minoxidil and finasteride are used for AGA, though the exact causes and evolutionary reasons for hairloss are unclear.